Both conventional and modified MicroScan Type 5 panels and Vitek Gram-Positive Susceptibility cards were compared with agar dilution screen plates for their abilities to detect high-level resistance to gentamicin and streptomycin in 235 enterococcal isolates, including 167 Enterococcusfaecalis and 63 E. faecium isolates. The modified Type 5 panels contained dextrose-phosphate broth instead of Mueller-Hinton broth in their high-level-resistance screen wells. The sensitivities for detection of gentamicin and streptomycin high-level resistance were 100 and 100% (E. faecalis) and 100 and 94% (E. faecium) for the modified MicroScan panels, 100 and 89% (E. faecalis) and 100 and 98% (E. faecium) for the conventional MicroScan panels, and 81 ant 86% (E. faecalis) and 85 and 94% (E. faecium) for the Vitek cards. All specificities were 100% except for the Vitek cards with streptomycin, where it was 96%. Isolates that showed resistance on the streptomycin agar screen plates were rescreened on plates containing 32,000 ,ug/ml to detect ribosomally mediated resistance. For all three systems, every failure to detect streptomycin high-level resistance occurred in isolates with enzymatic, not ribosomal, resistance. The modified MicroScan Type 5 panels are a suitable method for detecting enterococcal high-level resistance to gentamicin and streptomycin. The Vitek cards are too insensitive for this purpose.
Enterococcal isolates from the blood and cerebrospinal fluid may indicate serious underlying infections such as endocarditis and meningitis (1, 7, 12, 17, 26) . These infections require synergistic therapy with a combination of penicillin or ampicillin and an aminoglycoside, most frequently gentamicin (8, 14, 17, 26) . For decades, many isolates have shown resistance to penicillin-streptomycin synergism, and, over the last 5 years, rising levels of resistance to penicillin-gentamicin synergism have been observed (9, 14, 18, 25, 27, 28, 30) . These effects are the result of high-level aminoglycoside resistance, which may be mediated by plasmid-encoded, drug-altering enzymes or, in the case of streptomycin, by ribosomal mutation (3-5, 10, 11, 13, 17) . The reported percentages of strains with resistance to synergism vary from 31 to 60% for streptomycin and 0 to 55% for gentamicin (14, 15, 17, 20, 23) . It is therefore important to test blood and cerebrospinal fluid isolates for such resistance (9, 10, 14, 17) . The gold standard for this determination is the time-kill study, but a more efficient screening procedure has been described: synergy failure is predicted by high-level resistance (HLR), which is defined as the ability of an enterococcal isolate to grow on agar containing 2,000 ,ug of the antibiotic in question per ml (16) . In addition to agar dilution, current methods of assaying for aminoglycoside MICs greater than 2,000 ,ug/ml include macrodilution, in-house and commercial microdilution, and highcontent disk susceptibility, with various media and inocula (6, 19, 21, 22, 24, 29 ,ug/ml to detect extreme HLR to streptomycin associated with altered ribosomes (4) . We also evaluated another commercially available method for detecting enterococcal HLR, i.e., the Vitek Gram-Posi- Statistical definitions. Sensitivity was defined as the ability of a method to detect HLR when HLR was present by our reference method, agar dilution (sensitivity = true HLR positives by particular method/total HLR positives by agar dilution). Specificity was defined as the ability of a method to report absence of HLR when it was absent by agar dilution (specificity = true HLR negatives by particular method/total HLR negatives by agar dilution).
RESULTS
A total of 235 isolates were tested: 167 E. faecalis, 63 probable E. faecium, 4 probable E. avium, and 1 E. gallinarum. Previous studies in our laboratory have shown that the Vitek GPI card used for identification identifies E. faecalis with high sensitivity and specificity; it is somewhat less accurate in subclassifying the remaining species into E. faecium and others (20) . All 235 strains were tested for gentamicin and streptomycin HLR with conventional MicroScan Type 5 panels containing MHB in the HLR wells, modified Type 5 panels with DPB in those wells, Vitek GPS cards, and agar dilution. One strain would not grow in the Vitek GPS card despite our two attempts. Table 1 gives the number of isolates, by species, showing HLR to gentamicin, streptomycin, or both drugs, as determined by our agar screen reference method. The sensitivities and specificities of all three methods for gentamicin and streptomycin HLR detection are given in Table 2 . In Table 3 are given the sensitivities of all three methods for detecting streptomycin HLR categorized by the following two different resistance mechanisms: enzymatic, with MICs between 2,000 and 32,000 ,ug/ml, and ribosomal, with MICs above 32,000 ,ug/ml. For all three methods, all failures to detect streptomycin HLR (lack of sensitivity) occurred in isolates with enzymatic resistance. or "fine granular growth" throughout the wells (indicating growth) from either "slight whiteness" or "clear broth" (indicating no growth). Although most isolates gave rise to easily interpretable wells, ambiguous cases did exist, especially in the conventional panels. To challenge the panels in a way consistent with normal laboratory work-flow, our data are based only on readings made after 20 h of incubation, but for some difficult strains we found that an additional 24 h of incubation clarified or changed the initial reading. (iii) The sensitivity of detection of HLR to streptomycin is dependent on the mechanism of resistance. The two versions of MicroScan panels and Vitek cards always detected strains with ribosomal HLR and streptomycin MICs greater than 32,000 p.g/ml. All three systems, however, occasionally failed to detect strains with enzymatic HLR and MICs between 2,000 and 32,000. The results of the evaluations of these systems may vary, therefore, depending in part on the proportion of isolates with these two mechanisms of streptomycin HLR.
All three strains for which the modified Type 5 panels failed to detect streptomycin HLR were probable E. faecium with streptomycin MICs of 4,000 pig/ml. For two of these strains, incubating the panel for an additional 24 h (total, 44 h) resulted in positive growth in the streptomycin HLR well.
For the same two strains, the conventional Type 5 panels detected streptomycin HLR where the modified panels failed, although the growth even in the conventional HLR wells was weak. It is thus possible that some strains of E. faecium, unlike the majority of enterococci, grow better at 20 h in MHB than DPB. In support of this is the fact that both the conventional Type 5 panels and the Vitek cards showed marginally better sensitivity with E. faecium. Nonetheless, the streptomycin HLR sensitivity of the modified Type 5 panels with E. faecium is quite good, i.e., 94%. Moreover, the percentage of E. faecium strains in our study, 26%, is much higher than the reported clinical prevalence (20) . Thus, even when the prevalence of streptomycin HLR in a given hospital is 50%, the modified Type 5 panels will show positive and negative predictive values greater than 99% when applied to clinical isolates with smaller numbers (i.e., 10%) of E. faecium.
The third of the three systems we tested, the Vitek GPS cards, performed least well, with sensitivities for detecting gentamicin and streptomycin HLR of 82 and 90%, respectively, and specificity for streptomycin HLR of 96%. It was the only system that failed to identify all instances of gentamicin HLR and the only system that lacked 100% specificity for both drugs.
In sum, we found that the MicroScan Type 5 panels modified with DPB were a sensitive and specific method for detecting enterococcal HLR to gentamicin and streptomycin. The conventional Type 5 panel with MHB performed less well, although considerably better than reported in a previous study (6) . The Vitek GPS cards performed poorly in detecting enterococcal HLR and cannot be recommended for this purpose. Failure to detect streptomycin HLR with any of the three methods occurred only with enzymatically mediated HLR and never with ribosomal HLR. The sensitivity of all three methods in detecting streptomycin HLR will depend somewhat on the proportions of strains with the two resistance mechanisms in a particular institution.
